Navigation Links
Progen Announces PI-88 Phase 2 Lung Cancer Results
Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that trial, patients were at high risk of disease recurrence but had no demonstrable disease present at the time of starting therapy with PI-88" he said. "We remain committed to the ongoing development of PI-88, especially given the exciting Phase 2 data seen in the primary liver cancer trial."

About Progen:

Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

Progen Information:

Justus Homburg

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Sarah Meibusch

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: sarahm@progen-pharma.com

Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / +61 422 916 422

E: rpiercy@bcg.com.au

Rebecca Wilson

Buchan Consulting

T: +61 417 382 391

E: rwilson@bcg.com.au

Media Relations USA:

Robert D. Stanislaro

Financial Dynamics

T: 212-850-5657

E: robert.stanislaro@fd.com

Investor Relations USA:

Evan Smith

Financial Dynamics

T: 212-850-5606

E: evan.smith@fd.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells ... are characterized by self-renewal and the capacity to differentiate ... relatively new discovery, as the first mouse embryonic stem ... was not until 1995 that the first culturing of ... stem cells were not produced until 2006 As a ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the way ... they are in for and they are often worried things won’t go well. More often ... for. This year’s Au Pair of the Year winner’s all commented how their Au Pairs ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination ... 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination ... garnering increased attention from all stakeholders in the development of new chemical entities. ...
(Date:2/12/2016)... CULVER CITY, California (PRWEB) , ... February 12, 2016 , ... ... to announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco ... and healthy way to stay hydrated before the big event. The invitation-only gifting suite, ...
Breaking Medicine News(10 mins):